An analysis of a US database shows that Black individuals who receive abiraterone acetate or enzalutamide for metastatic castration-resistant prostate cancer have better overall survival than their White counterparts.
Stereotactic body radiotherapy has a favorable long-term disease control and safety profile in the setting of low- or intermediate-risk prostate cancer, say US researchers who analyzed individual patient data from over 2000 prospectively treated men.
Immune checkpoint inhibitor therapy is well tolerated by patients with HIV infection and advanced-stage cancer and does not appear to adversely affect HIV viral load or CD4 cell count, suggest results of a systematic data review.
Children conceived using assisted reproductive technology do not have an increased cancer risk relative to either the general population or naturally conceived children of women with impaired fertility, shows a Dutch study with a long follow-up.
Supplementing androgen deprivation therapy with docetaxel does not appear to improve the outcomes of men with high-risk nonmetastatic prostate cancer and rising prostate-specific antigen levels after treatment, indicate phase III trial findings.
Use of the cyclooxygenase 2 inhibitor celecoxib during neoadjuvant taxane-based chemotherapy is associated with adverse survival outcomes in certain subgroups of patients with breast cancer, shows a post-hoc analysis of the REMAGUS02 trial.
A web-based patient-reported system for monitoring symptoms after treatment for lung cancer is associated with significantly better overall survival than standard scheduled imaging, trial results show.
The development of immune-related adverse events is associated with better outcomes in response to programmed cell death protein 1 inhibitor monotherapy across a range of tumour types, suggests a chart review.
The level of mesenchymal epithelial transition factor copy number gain does not affect response to tyrosine kinase inhibitors in patients with metastatic epidermal growth factor receptor-mutated non-small-cell lung cancer, research shows.
A population-based study has not replicated the previously reported association between Alzheimer’s dementia and androgen deprivation therapy, but suggests that the risk for non-Alzheimer’s dementia may be elevated with use of gonadotropin-releasing hormone agonists and orchiectomy.
The prevalence of hepatitis B virus and hepatitis C virus infection in patients with newly diagnosed cancer is similar to that of the US population, but a “substantial proportion” of patients are unaware of their infection, research shows.
Patients with previously untreated intermediate- or poor-risk advanced renal cell carcinoma derive greater health-related quality of life benefits from nivolumab plus ipilimumab than from sunitinib, CheckMate 214 data show.
Tumour-infiltrating lymphocytes could serve as a prognostic marker in patients with early-stage HER2-positive breast cancer being treated with chemotherapy plus trastuzumab, indicates an analysis of the ShortHER trial comparing 9 weeks of trastuzumab with the standard 1-year regimen.
Tumor mutational burden could be a cross-tumor predictive biomarker of immunotherapy, say US researchers who found an association between mutational load and survival across a wide range of malignancies treated with immune checkpoint inhibitors.
Second-line treatment with vascular endothelial growth factor receptor–tyrosine kinase inhibitors after failure of nivolumab plus ipilimumab continues to benefit patients with metastatic renal cell carcinoma, report researchers.